miércoles, 29 de julio de 2015

Lupus y embarazo/Pregnancy and lupus

Embarazo asociado con lupus eritematoso sistémico. Tolerancia immune en el embarazo y su deficiencia en lupus eritematoso sistémico. Un dilemma inmunológico
Pregnancy Associated with Systemic Lupus Erythematosus: Immune Tolerance in Pregnancy and Its Deficiency in Systemic Lupus Erythematosus-An Immunological Dilemma.
J Immunol Res. 2015;2015:241547. doi: 10.1155/2015/241547. Epub 2015 May 18.
Abstract
Pregnancy is a physiological condition that requires immune tolerance to the product of conception. Systemic lupus erythematosus (SLE) is a disease with well-represented immune mechanisms that disturb immune tolerance. The association of pregnancy with systemic lupus erythematosus creates a particular immune environment in which the immune tolerance specific of pregnancy is required to coexist with alterations of the immune system caused by SLE. The main role is played by T regulatory (Treg) cells, which attempt to regulate and adapt the immune system of the mother to the new conditions of pregnancy. Other components of the immune system also participate to maintain maternal-fetal immune tolerance. If the immune system of pregnant women with SLE is not able to maintain maternal immune tolerance to the fetus, pregnancy complications (miscarriage, fetal hypotrophy, and preterm birth) or maternal complications (preeclampsia or activation of SLE, especially in conditions of lupus nephritis) may occur. In certain situations this can be responsible for neonatal lupus. At the same time, it must be noted that during pregnancy, the immune system is able to achieve immune tolerance while maintaining the anti-infectious immune capacity of the mother. Immunological monitoring of pregnancyduring SLE, as well as of the mother's disease, is required. It is important to understand immune tolerance to grafts in transplant pathology.
Cesárea en un caso de lupus eritematoso sistémico
Caesarean section in a case of systemic lupus erythematosus.
Indian J Anaesth. 2014 Mar;58(2):193-5. doi: 10.4103/0019-5049.130827.
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease most frequently found in women of child bearing age and may co-exist with pregnancy. Disease exacerbation, increased foetal loss, neonatal lupus and an increased incidence of pre-eclampsia are the major challenges. Its multisystem involvement and therapeutic interventions like anticoagulants, steroids and immunosuppressive agents pose a high risk for both surgery and anaesthesia. We describe successful management of an antinuclear antibody (ANA) positive parturient with bad obstetric history who underwent elective caesarean section under spinal anaesthesia.
KEYWORDS: Autoimmune; LSCS; pregnancy; systemic lupus erythematosus
Lupus eritematoso sistémico en la paciente gestante. Implicaciones anestésicas
E.M. Pastor Tomás, J. Guillén Antón, A. Vaquerizo Gareta, P. Lirola Grajales, R. Martínez García y J. Cuartero Lobera
Rev. Esp. Anestesiol. Reanim. 2001; 48: 141-145
Lupus y embarazo. Mitos y evidencias
Mary-Carmen Amigo Castañeda
An Med Asoc Med Hosp ABC 1999; 44 (4): 183-191
Enfermedad reumatológica y embarazo
Carlos-Enrique Toro Gutiérrez, Mario Andrés Quintana Duque, María Fernanda Escobar, Carlos Alberto Cañas Dávila, Antonio Iglesias Gamarra, José Félix Restrepo
Rev.Colomb.Reumatol. vol.14 no.1 Bogotá Jan./Mar. 2007
Lupus eritematoso sistémico en obstetricia. Implicaciones para el anestesiólogo
Systemic lupus erythematosus and the obstetrical patient--implications for the anaesthetist.
Can J Anaesth. 1991 Sep;38(6):790-5.
Abstract
Systemic lupus erythematosus (SLE) is a multisystem, chronic inflammatory disease characterized by autoantibody production. The disease is most frequently found in women of childbearing age and therefore may co-exist with pregnancy. The clinical manifestations of the disease are variable and depend on the severity of damage to organ systems such as musculoskeletal, renal, haematological, neurological, cardiac, and respiratory. Many patients require drugs such as aspirin or prednisone. The pregnant patient may experience exacerbations of the disease, neonatal loss, and obstetrical complications such as pre-eclampsia. Patients with the Lupus Anticoagulant are at risk for an abnormal perinatal course. The anaesthetic management will depend on the patient's clinical status and the well-being of the fetus. The patient should be examined to determine the extent of end organ damage, current medications, and the health of the fetus. Laboratory investigations such as a coagulation screen and tests of renal function should be performed before anaesthetic intervention if time permits. A multidisciplinary approach to care of the patient and resources to manage complications are essential to optimize the outcome for both mother and newborn.
PDF
Atentamente
Anestesia y Medicina del Dolor

lunes, 27 de julio de 2015

Dr Carlos Jorquera / Reunión Bianual 2015. Congreso de la Asociación Mexicana de Cirugía de la Mano AC

La reunión bianual 2015, de la Asociación Mexicana de Cirugía de la Mano AC,
Esta avalada por el Consejo Mexicano de Ortopedia y Traumatología y otorga 3 puntos validos para la re-certificación, ademas este año tenemos como invitado internacional al dr Carlos Jorquera de Chile, el cual es Jefe de la Unidad de Mano y Micro-cirugía de la Clínica Alemana de Santiago.
‪#‎amcmano2015‬
Inscribete ya!!!
http://amcmano.org/congreso2015/registro/view/index.php



VALORACIÓN DE RESULTADOS EN CIRUGÍA DE LA MANO. Dra. Ma. Francisca Vázquez Alonso



‪#‎amcmano2015‬
http://www.amcmano.org/congreso2015/
http://amcmano.org/congreso2015/registro/view/index.php

Es tiempo de inscribirse!!!
VALORACIÓN DE RESULTADOS EN CIRUGÍA DE LA MANO. Dra. Ma. Francisca Vázquez Alonso, es nuestra tercera platica del jueves 3 de septiembre de este 2015, durante el desarrollo de la Reunión bianual 2015, de la asociación Mexicana de Cirugía de la Mano AC presidida este bienio 2014-2015 por el dr Jesús riseño, la cual se llevará a cabo en el auditorio de la facultad de medicina de la UAEM, junto a la cruz roja de Cuernavaca, el 3, 4 y 5 septiembre.

Más de sugammadex/More on sugammadex

Beneficios y riesgos de sugammadex
Benefits and risks of sugammadex.
Korean J Anesthesiol. 2015 Feb;68(1):1-2. doi: 10.4097/kjae.2015.68.1.1.
Uso de sugammadex en un paciente con syndrome de Wolff-Parkinson-White
Sugammadex Use in a Patient with Wolff-Parkinson-White (WPW) Syndrome.
Balkan Med J. 2015 Jul;32(3):327-9. doi: 10.5152/balkanmedj.2014.15155. Epub 2015 Jul 1.
Abstract
BACKGROUND: Wolff-Parkinson-White (WPW) syndrome is a disease associated with episodes of supraventricular tachycardia and ventricular pre-excitation or atrial fibrillation. WPW is characterized by an aberrant electrical conduction pathway between atria and ventricles. CASE REPORT: The major anesthetic problem connected with WPW syndrome is the risk of tachyarrhythmias due to accessory pathway. Therefore, it has been proposed that the aim of anesthetic management should be the avoidance of tachyarrhythmia and sympathetic stimulation.Sugammadex was administered as a neuromuscular reversal agent in this case. To our knowledge, this is the first case report of sugammadex use in a patient with WPW. This report presents a case of general anesthesia management in a patient with WPW syndrome.CONCLUSION: We think that it is appropriate to use sugammadex to reverse rocuronium for the prevention of sudden hemodynamic changes in patients with WPW who underwent general anesthesia.
KEYWORDS: General anesthesia; Wolff-Parkinson-White syndrome; sugammadex
Un milagro que acelera la funcionalidad de la sala de operaciones: Sugammadex
A miracle that accelerates operating room functionality: sugammadex.
Biomed Res Int. 2014;2014:945310. doi: 10.1155/2014/945310. Epub 2014 Aug 14.
Abstract
BACKGROUND: Sugammadex offers a good alternative to the conventional decurarisation process currently performed with cholinesterase inhibitors. Sugammadex, which was developed specifically for the aminosteroid-structured rocuronium and vecuronium neuromuscular blockers, is a modified cyclodextrin made up of 8 glucose monomers arranged in a cylindrical shape. METHODS: In this study, the goal was to investigate the efficacy of sugammadex. Sugammadex was used when there was insufficient decurarisation following neostigmine. This study was performed on 14 patients who experienced insufficient decurarisation (TOF <0.9) with neostigmine after general anaesthesia in the operating rooms of a university and a state hospital between June, 2012, and January, 2014. A dose of 2mg/kg of sugammadex was administered. RESULTS: Time elapsed until sugammadex administration following neostigmine 37 ± 6 min, following sugammadex it took 2.1 ± 0.9 min to reach TOF ≥0.9, and the extubation time was 3.2 ± 1.4 min. No statistically significant differences were detected in the hemodynamic parameters before and after sugammadex application. From the time of administration of sugammadex to the second postoperative hour, no side effects or complications occurred. None of the patients experienced acute respiratory failure or residual block during this time period. CONCLUSION: Sugammadex was successfully used to reverse rocuronium-induced neuromuscular block in patients where neostigmine was insufficient.
Sugammadex y peso ideal en cirugía bariátrica
Sugammadex and ideal body weight in bariatric surgery.
Anesthesiol Res Pract. 2013;2013:389782. doi: 10.1155/2013/389782. Epub 2013 Jun 6.
Atentamente
Anestesia y Medicina del Dolor

viernes, 24 de julio de 2015

Avances en la comprensión y el tratamiento de las enfermedades del hígado durante el embarazo: Una revisión.

Avances en la comprensión y el tratamiento de las enfermedades del hígado durante el embarazo: Una revisión.
Advances in understanding and treating liver diseases during pregnancy: A review.
Kamimura K, Abe H, Kawai H, Kamimura H, Kobayashi Y, Nomoto M, Aoyagi Y, Terai S.
World J Gastroenterol. 2015 May 7;21(17):5183-90. doi: 10.3748/wjg.v21.i17.5183.
Abstract
Liver disease in pregnancy is rare but pregnancy-related liver diseases may cause threat to fetal and maternal survival. It includes pre-eclampsia;eclampsia; haemolysis, elevated liver enzymes, and low platelets syndrome; acute fatty liver of pregnancy; hyperemesis gravidarum; and intrahepatic cholestasis of pregnancy. Recent basic researches have shown the various etiologies involved in this disease entity. With these advances, rapid diagnosis is essential for severe cases since the decision of immediate delivery is important for maternal and fetal survival. The other therapeutic options have also been shown in recent reports based on the clinical trials and cooperation and information sharing between hepatologist and gynecologist is important for timely therapeutic intervention. Therefore, correct understandings of diseases and differential diagnosis from the pre-existing and co-incidental liver diseases during the pregnancy will help to achieve better prognosis. Therefore, here we review and summarized recent advances in understanding the etiologies, clinical courses and management of liver disease in pregnancy. This information will contribute to physicians for diagnosis of disease and optimum management of patients.
KEYWORDS: Acute fatty liver of pregnancy; Haemolysis elevated liver enzymes; Hyperemesis gravidarum; Intrahepatic cholestasis of pregnancy; Liver injury; Low platelets; Pregnancy
PDF
Hepatopatías relacionadas al embarazo
Pregnancy-related liver disorders.
Goel A, Jamwal KD, Ramachandran A, Balasubramanian KA, Eapen CE.
J Clin Exp Hepatol. 2014 Jun;4(2):151-62. doi: 10.1016/j.jceh.2013.03.220. Epub 2013 Mar 16.
Abstract
Pregnancy-related liver disorders accounted for 8% of all maternal deaths at our center from 1999 to 2011. Of the three pregnancy-related liver disorders (acute fatty liver of pregnancy (AFLP), HELLP (Hemolysis, elevated liver enzymes, low platelets) syndrome and pre-eclamptic liver dysfunction, which can lead to adverse maternal and fetal outcome, AFLP is most typically under - diagnosed. Risk of maternal death can be minimised by timely recognition and early/aggressive multi-specialty management of these conditions. Urgent termination of pregnancy remains the cornerstone of therapy for some of these life threatening disorders, but recent advancements in our understanding help us in better overall management of these patients. This review focuses on various aspects of pregnancy-related liver disorders.
PDF
Atentamente
Anestesia y Medicina del Dolor

Dra. Virginia Apgar una vida ejemplar

Estimado Pediatra te invito al Seminario de Pediatría, Cirugía Pediátrica y Lactancia Materna. El día 29 de Julio 2015 las 21hrs (Centro, México DF, Guadalajara y Lima Perú) a la Conferencia: “Dra. Virginia Apgar una vida ejemplar” por la “Dra. Rosaura Del Valle Avilez”, Pediatra de la Cd. de Tlaxcala. La sesión inicia puntualmente las 21 hrs.
Para entrar a la Sala de Conferencia:
1.- hacer click en la siguiente liga, o cópiala y escríbela en tu buscador http://connectpro60196372.adobeconnect.com/virginia_apgar/
2.- “Entra como Invitado” Escribes tu nombre y apellido en el espacio en blanco
3.- Hacer click en el espacio que dice “Entrar en la Sala”
5.- A disfrutar la conferencia
6.- Recomendamos que dejes tu Nombre Completo, Correo electrónico y que participes.


Henrys


Dr. Enrique Mendoza López
Webmaster: CONAPEME
Coordinador Nacional: Seminario Ciberpeds-Conapeme
Av La clinica 2520-310
Colonia Sertoma ,Mty N.L. México
CP 64710
Tel-Fax 52 81 83482940 y 52 81 81146053
Celular 8183094806
www.conapeme.org
www.pediatramendoza.com
enrique@pediatramendoza.com
emendozal@yahoo.com.mx

Desentrañando las teorías de la preeclampsia: son las vías de protección del nuevo paradigma?

Desentrañando las teorías de la preeclampsia: son las vías de protección del nuevo paradigma?
Unravelling the theories of pre-eclampsia: are the protective pathways the new paradigm?
Ahmed A, Ramma W.
Br J Pharmacol. 2015 Mar;172(6):1574-86. doi: 10.1111/bph.12977.
Abstract
Pre-eclampsia is a vascular disorder of pregnancy where anti-angiogenic factors, systemic inflammation and oxidative stress predominate, but none can claim to cause pre-eclampsia. This review provides an alternative to the 'two-stage model' of pre-eclampsia in which abnormal spiral arteries modification leads to placental hypoxia, oxidative stress and aberrant maternal systemic inflammation. Very high maternal soluble fms-like tyrosine kinase-1 (sFlt-1 also known as sVEGFR) and very low placenta growth factor (PlGF) are unique to pre-eclampsia; however, abnormal spiral arteries and excessive inflammation are also prevalent in other placental disorders. Metaphorically speaking, pregnancy can be viewed as a car with an accelerator and brakes, where inflammation, oxidative stress and an imbalance in the angiogenic milieu act as the 'accelerator'. The 'braking system' includes the protective pathways of haem oxygenase 1 (also referred as Hmox1 or HO-1) and cystathionine-γ-lyase (also known as CSE or Cth), which generate carbon monoxide (CO) and hydrogen sulphide (H2S) respectively. The failure in these pathways (brakes) results in the pregnancy going out of control and the system crashing. Put simply, pre-eclampsia is an accelerator-brake defect disorder. CO and H2S hold great promise because of their unique ability to suppress the anti-angiogenic factors sFlt-1 and soluble endoglin as well as to promote PlGF and endothelial NOS activity. The key to finding a cure lies in the identification of cheap, safe and effective drugs that induce the braking system to keep the pregnancy vehicle on track past the finishing line.
PDF
Atentamente
Anestesia y Medicina del Dolor

TÉCNICAS ANESTÉSICAS EN CIRUGÍA DE MANO. Dra. Elizabeth Wing / Reunión Bianual 2015, Congreso de la Asociación Mexicana de Cirugía de la Mano AC


Buenos días estimados amigos en la red, nuevamente les recuerdo la Reunión Bianual 2015 que celebra el congreso de la Asociación Mexicana de Cirugía de la Mano AC, en esta ocasión se llevará a cabo en la ciudad de Cuernavaca Morelos, en el auditorio de la facultad de medicina de la UAEM, junto a la cruz roja, una zona muy segura de la ciudad, , la segunda platica que tendrmos en dicha reunión será:
TÉCNICAS ANESTÉSICAS EN CIRUGÍA DE MANO. Dra. Elizabeth Wing

miércoles, 22 de julio de 2015

ML supreme en resucitación neonatal. Estudio randomizado y controlado

ML supreme en resucitación neonatal. Estudio randomizado y controlado
LMA Supreme for neonatal resuscitation: study protocol for a randomized controlled trial.
Trials. 2014 Jul 15;15:285. doi: 10.1186/1745-6215-15-285.
Abstract
BACKGROUND:
The most important action in the resuscitation of a newborn in the delivery room is to establish effective assisted ventilation. The face mask and endotracheal tube are the devices used to achieve this goal. Laryngeal mask airways that fit over the laryngeal inlet have been shown to be effective for ventilating newborns at birth and should be considered as an alternative to facemask ventilation or endotracheal intubation among newborns weighing >2,000 g or delivered ≥34 weeks' gestation. A recent systematic review and meta-analysis of supraglottic airways in neonatal resuscitation reported the results of four randomized controlled trials (RCTs) stating that fewer infants in the group using laryngeal maskairways required endotracheal intubation (1.5%) compared to the group using face masks (12.0%). However, there were methodological concerns over all the RCTs including the fact that the majority of the operators in the trials were anesthesiologists.Our hypothesis is based on the assumption that ventilating newborns needing positive pressure ventilation with a laryngeal mask airway will be more effective than ventilating with a face maskin a setting where neonatal resuscitation is performed by midwives, nurses, and pediatricians. The primary aim of this study will be to assess the effectiveness of the laryngeal mask airway over the face mask in preventing the need for endotracheal intubation. METHODS/DESIGN: This will be an open, prospective, randomized, single center, clinical trial. In this study, 142 newborns weighing >1,500 g or delivered ≥34 weeks gestation needing positive pressure ventilation at birth will be randomized to be ventilated with a laryngeal mask airway (LMA SupremeTM, LMA Company, UK - intervention group) or with a face mask (control group). PRIMARY OUTCOME: Proportion of newborns needing endotracheal intubation. SECONDARY OUTCOMES:
Apgar score at 5 minutes, time to first breath, onset of the first cry, duration of resuscitation, death or moderate to severe hypoxic-ischemic encephalopathy within 7 days of life.
Atentamente
Anestesia y Medicina del Dolor

Embarazo patológico / Pathological pregnancy

La carga de la eclampsia: resultados de un estudio multicéntrico sobre la vigilancia de la morbilidad materna severa en Brasil.
The burden of eclampsia: results from a multicenter study on surveillance of severe maternal morbidity in Brazil.
Giordano JC, Parpinelli MA, Cecatti JG, Haddad SM, Costa ML, Surita FG, Pinto E Silva JL, Sousa MH.
PLoS One. 2014 May 13;9(5):e97401. doi: 10.1371/journal.pone.0097401. eCollection 2014.
Abstract
OBJECTIVE: Maternal mortality (MM) is a core indicator of disparities in women's rights. The study of Near Miss cases is strategic to identifying the breakdowns in obstetrical care. In absolute numbers, both MM and occurrence of eclampsia are rare events. We aim to assess the obstetric care indicators and main predictors for severe maternal outcome from eclampsia (SMO: maternal death plus maternal near miss). METHODS: Secondary analysis of a multicenter, cross-sectional study, including 27 centers from all geographic regions of Brazil, from 2009 to 2010. 426 cases of eclampsia were identified and classified according to the outcomes: SMO and non-SMO. We classified facilities as coming from low- and high-income regions and calculated the WHO's obstetric health indicators. SPSS and Stata softwares were used to calculate the prevalence ratios (PR) and respective 95% confidence interval (CI) to assess maternal characteristics, clinical and obstetrical history, and access to health services as predictors for SMO, subsequently correlating them with the corresponding perinatal outcomes, also applying multiple regression analysis (adjusted for cluster effect). RESULTS: Prevalence of and mortality indexes for eclampsia in higher and lower income regions were 0.2%/0.8% and 8.1%/22%, respectively. Difficulties in access to health care showed that ICU admission (adjPR 3.61; 95% CI 1.77-7.35) and inadequate monitoring (adjPR 2.31; 95% CI 1.48-3.59) were associated with SMO. CONCLUSIONS: Morbidity and mortality associated with eclampsia were high in Brazil, especially in lower income regions. Promoting quality maternal health care and improving the availability of obstetric emergency care are essential actions to relieve the burden of eclampsia.
PDF
Hipertensión crónica y evolución del embarazo. Revisión sistemática y meta-análisis
Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis.
Bramham K, Parnell B, Nelson-Piercy C, Seed PT, Poston L, Chappell LC.
BMJ. 2014 Apr 15;348:g2301. doi: 10.1136/bmj.g2301.
Abstract
OBJECTIVE: To provide an accurate assessment of complications of pregnancy in women with chronic hypertension, including comparison with population pregnancy data (US) to inform pre-pregnancy and antenatal management strategies. DESIGN: Systematic review and meta-analysis.
DATA SOURCES: Embase, Medline, and Web of Science were searched without language restrictions, from first publication until June 2013; the bibliographies of relevant articles and reviews were hand searched for additional reports. STUDY SELECTION: Studies involving pregnant women with chronic hypertension, including retrospective and prospective cohorts, population studies, and appropriate arms of randomised controlled trials, were included. DATA EXTRACTION: Pooled incidence for each pregnancy outcome was reported and, for US studies, compared with US general population incidence from the National Vital Statistics Report (2006).
RESULTS: 55 eligible studies were identified, encompassing 795,221 pregnancies. Women with chronic hypertension had high pooled incidences of superimposed pre-eclampsia (25.9%, 95% confidence interval 21.0% to 31.5 %), caesarean section (41.4%, 35.5% to 47.7%), preterm delivery <37 weeks' gestation (28.1% (22.6 to 34.4%), birth weight <2500 g (16.9%, 13.1% to 21.5%), neonatal unit admission (20.5%, 15.7% to 26.4%), andperinatal death (4.0%, 2.9% to 5.4%). However, considerable heterogeneity existed in the reported incidence of all outcomes (τ(2)=0.286-0.766), with a substantial range of incidences in individual studies around these averages; additional meta-regression did not identify any influential demographic factors. The incidences (the meta-analysis average from US studies) of adverse outcomes in women with chronic hypertension were compared with women from the US national population dataset and showed higher risks in those with chronic hypertension: relative risks were 7.7 (95% confidence interval 5.7 to 10.1) for superimposed pre-eclampsia compared with pre-eclampsia, 1.3 (1.1 to 1.5) for caesarean section, 2.7 (1.9 to 3.6) for preterm delivery <37 weeks' gestation, 2.7 (1.9 to 3.8) for birth weight <2500 g, 3.2 (2.2 to 4.4) for neonatal unit admission, and 4.2 (2.7 to 6.5) for perinatal death. CONCLUSIONS: This systematic review, reporting meta-analysed data from studies of pregnant women with chronic hypertension, shows that adverse outcomes of pregnancy are common and emphasises a need for heightened antenatal surveillance. A consistent strategy to study women with chronic hypertension is needed, as previous study designs have been diverse. These findings should inform counselling and contribute to optimisation of maternal health, drug treatment, and pre-pregnancy management in women affected by chronic hypertension.
PDF
Anticuerpos antifosfolípidos y síndrome antifosfolípido durante en embarazo. Conceptos de diagnóstico
Antiphospholipid Antibodies and Antiphospholipid Syndrome during Pregnancy: Diagnostic Concepts.
Levy RA, Dos Santos FC, de Jesús GR, de Jesús NR.
Front Immunol. 2015 May 7;6:205. doi: 10.3389/fimmu.2015.00205. eCollection 2015.
Abstract
Antiphospholipid syndrome (APS) comprises of a wide spectrum of clinical and obstetric manifestations linked to the presence of antiphospholipid antibodies (aPL). APS was described in the context of lupus, and later as an isolated syndrome or primary APS. The presence of aPL, especially the lupus anticoagulant test, is associated with adverse pregnancy outcomes, such as fetal death, recurrent early miscarriages, pre-eclampsia, and placental insufficiency, but does not seem to influence infertility. High quality scientific data to support these associations, however, are lacking, and controversies arise about the definition of positive aPL (low vs medium-high titers) or even the definition of the adverse events. This reviewdiscusses APS classification criteria and the current debate about it.
KEYWORDS: antiphospholipid antibodies; antiphospholipid syndrome; fetal death; recurrent early miscarriage
PDF
Atentamente
Anestesia y Medicina del Dolor